Next report date
Report period
Q2 2024
EPS estimate
−2.78SEK
Revenue estimate
54.27 MSEK
−16.08SEK
−831.72 MSEK
134.09 MSEK
45.82 M
About HANSA BIOPHARMA AB
Sector
CEO
Søren Tulstrup
Headquarters
Lund
Website
Employees (FY)
168
Founded
2007
ISIN
SE0002148817
FIGI
BBG00G4XFQG6
Hansa Biopharma AB focuses on novel immunomodulatory enzymes, which treat rare immunoglobulin G-mediated autoimmune conditions, transplant rejection and cancer. Its pipeline includes IdeS, HBP-assay, EnzE, and NiceR. The company was founded by Lars Björck and Bo Krister Håkansson in 2001 and is headquartered in Lund, Sweden.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 0RC7 is 28.64 SEK — it has decreased by 0.62% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on LSIN exchange HANSA BIOPHARMA AB NPV stocks are traded under the ticker 0RC7.
HANSA BIOPHARMA AB NPV is going to release the next earnings report on Jul 18, 2024. Keep track of upcoming events with our Earnings Calendar.
0RC7 stock is 0.98% volatile and has beta coefficient of −0.79. Check out the list of the most volatile stocks — is HANSA BIOPHARMA AB NPV there?
0RC7 earnings for the last quarter are −2.40 SEK per share, whereas the estimation was −3.72 SEK resulting in a 35.44% surprise. The estimated earnings for the next quarter are −3.46 SEK per share. See more details about HANSA BIOPHARMA AB NPV earnings.
HANSA BIOPHARMA AB NPV revenue for the last quarter amounts to 50.40 M SEK despite the estimated figure of 44.06 M SEK. In the next quarter revenue is expected to reach 54.04 M SEK.
Yes, you can track HANSA BIOPHARMA AB NPV financials in yearly and quarterly reports right on TradingView.
0RC7 stock has risen by 0.99% compared to the previous week, the month change is a 1.65% fall, over the last year HANSA BIOPHARMA AB NPV has showed a 40.88% decrease.
0RC7 net income for the last quarter is −218.58 M SEK, while the quarter before that showed −124.46 M SEK of net income which accounts for −75.62% change. Track more HANSA BIOPHARMA AB NPV financial stats to get the full picture.
Today HANSA BIOPHARMA AB NPV has the market capitalization of 1.53 B, it has decreased by 4.80% over the last week.
No, 0RC7 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, 0RC7 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade HANSA BIOPHARMA AB NPV stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 30, 2024, the company has 168.00 employees. See our rating of the largest employees — is HANSA BIOPHARMA AB NPV on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So HANSA BIOPHARMA AB NPV technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating HANSA BIOPHARMA AB NPV stock shows the sell signal. See more of HANSA BIOPHARMA AB NPV technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on HANSA BIOPHARMA AB NPV future price: according to them, 0RC7 price has a max estimate of 175.00 SEK and a min estimate of 68.00 SEK. Read a more detailed HANSA BIOPHARMA AB NPV forecast: see what analysts think of HANSA BIOPHARMA AB NPV and suggest that you do with its stocks.